Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (77)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sleijfer, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sleijfer, S.
(Chest. 2001;120:617-624.)
© 2001 American College of Chest Physicians

Bleomycin-Induced Pneumonitis*

Stefan Sleijfer, MD, PhD

* From the Department of Internal Medicine, Sint Franciscus Gasthuis, Rotterdam, The Netherlands.

Correspondence to: Stefan Sleijfer, MD, PhD, Department of Internal Medicine, Sint Franciscus Gasthuis, Kleiweg 500, 3045 PM Rotterdam, The Netherlands; e-mail: sleijfer{at}hotmail.com


   Abstract
TOP
 Abstract
Introduction
 Clinical Features
 Pathogenesis
 Pulmonary Function Assessments
 Risk Factors
 Prevention and Treatment of...
 Conclusion
 References
 
The cytotoxic agent bleomycin is feared for its induction of sometimes fatal pulmonary toxicity, also known as bleomycin-induced pneumonitis (BIP). The central event in the development of BIP is endothelial damage of the lung vasculature due to bleomycin-induced cytokines and free radicals. Ultimately, BIP can progress in lung fibrosis. The diagnosis is established by a combination of clinical symptoms, radiographic alterations, and pulmonary function test results, while other disorders resembling BIP have to be excluded. Pulmonary function assessments most suitable for detecting BIP are those reflecting lung volumes. The widely used transfer capacity of the lungs for carbon monoxide appeared recently not to be specific when bleomycin is used in a polychemotherapeutic regimen. There are no proven effective treatments for BIP in humans, although corticosteroids are widely applied. When patients survive BIP, they almost always recover completely with normalization of radiographic and pulmonary function abnormalities. This review focuses on BIP, especially on the pathogenesis, risk factors, and its detection.

Key Words: bleomycin • pneumonitis • pulmonary toxicity


   Introduction
TOP
 Abstract
 Introduction
Clinical Features
 Pathogenesis
 Pulmonary Function Assessments
 Risk Factors
 Prevention and Treatment of...
 Conclusion
 References
 
Bleomycin is an antibiotic agent with antitumor activity discovered by Umezewa et al1 in 1966 and was originally isolated from the fungus Streptomyces verticillus. It is commonly used as part of the cytostatic treatment of several tumor types, such as germ-cell tumors, lymphomas, Kaposi’s sarcoma, cervical cancer, and squamous cell carcinomas of head and neck.

Bleomycin exerts its antitumor effect by inducing tumor cell death, while inhibition of tumor angiogenesis may also be important.2 Its cytotoxicity occurs by induction of free radicals. Bleomycin forms a complex with Fe (II), which is subsequently oxidized to Fe (III), resulting in reduction of oxygen to free radicals. These free radicals cause DNA breaks leading to cell death ultimately.3 4 5 Bleomycin can be given by several routes: IV, IM, or subcutaneously; in case of malignant effusion, it can be administered intrapleurally or intraperitoneally. The elimination of bleomycin is mainly by the kidneys; in the first 24 h after its administration, approximately 60% of unchanged drug is excreted.6 Furthermore, bleomycin can be deactivated by the enzyme bleomycin hydrolase, which can be found predominantly in the liver, spleen, bone marrow, and intestine.7

The application of bleomycin is featured by the occurrence of sometimes fatal side effects. Due to the lack of the bleomycin-inactivating enzyme, bleomycin hydrolase, in the lungs and the skin,8 bleomycin-induced toxicity occurs predominantly in these organs. Directly after its administration, the occurrence of fever, chills, and sometimes hypotension is well known.9 10 Other side effects are dermal hyperpigmentation and fibrosis, stomatitis, and fatigue.11 The most feared and dose-limiting side effect of bleomycin is its induction of pulmonary toxicity. Several distinct pulmonary syndromes have been associated with the use of bleomycin, such as bronchiolitis obliterans with organizing pneumonia (BOOP),12 eosinophilic hypersensitivity,13 and, most commonly, interstitial pneumonitis, which ultimately may progress into fibrosis. The latter, bleomycin-induced pneumonitis (BIP), occurs in 0 to 46% of the patients treated with bleomycin-containing chemotherapy, depending on the criteria used for the diagnosis.14 15 16 17 18 The mortality of patients with BIP has been reported to be approximately 3% of all patients treated with bleomycin.18 19 This review will focus on BIP, especially on its pathogenesis, risk factors, and the detection by pulmonary function assessments.


   Clinical Features
TOP
 Abstract
 Introduction
 Clinical Features
Pathogenesis
 Pulmonary Function Assessments
 Risk Factors
 Prevention and Treatment of...
 Conclusion
 References
 
Often, BIP starts gradually during treatment, but the development of BIP up to 6 months after discontinuation of bleomycin therapy has also been reported.20 The clinical diagnosis of BIP is rather hampered by its resemblance to other conditions often encountered in cancer patients, such as pneumonia, pulmonary metastases, or lymphangitic carcinoma.

Patients with BIP present initially with a nonproductive cough, exertional dyspnea, and sometimes fever. With progressive pneumonitis, dyspnea at rest, tachypnea, and cyanosis may occur. At physical examination, fine bibasilar crepitations can be found initially, progressing to rhonchi and sometimes pleural rubbing.17

Typical chest radiographic findings are bilateral, bibasilar infiltrates, sometimes followed by diffuse interstitial and alveolar infiltrates, and lobar consolidation ultimately. However, BIP can also present with unilateral abnormalities and focal infiltrates.17 21

On CT scanning, bleomycin-induced alterations may appear earlier than on chest radiographs. In most patients, small linear and subpleural nodular lesions in the lung bases are noticed.22

Histologic material, for instance, obtained by transbronchial biopsies is often not conclusive. There are no real pathognomic alterations, but the most characteristic lesions are squamous metaplasia of bronchiolar epithelium, inflammatory cells infiltrating into alveoli and alveolar septa, edema plus focal collagen depositions in these septa, and fibrotic areas.23 24

Because of the resemblance of the symptoms of BIP with other diseases, the diagnosis of BIP is often one of exclusion. Other diseases are often excluded by culture and Gram-staining of sputum, polymerase chain reaction on pathogens such as viruses, or serology or determination of antigens of pathogens leading to a specific pneumonia. Often these patients have been treated unsuccessfully with antibiotics because of the suspicion of pneumonia before the diagnosis BIP is established. When patients survive the episode of BIP, they almost always recover completely with disappearance of symptoms, signs, and pulmonary function disturbances.17 25


   Pathogenesis
TOP
 Abstract
 Introduction
 Clinical Features
 Pathogenesis
Pulmonary Function Assessments
 Risk Factors
 Prevention and Treatment of...
 Conclusion
 References
 
The pathogenesis of BIP has been intensively studied in animals, but data derived from human studies are scarce. In animals, the first event noted is endothelial damage of the lung vasculature accompanied by edema.26 This is followed by influx of inflammatory cells such as macrophages, lymphocytes, and neutrophils into the lung parenchyma and subsequently by fibroblasts leading to pulmonary fibrosis.26 Studies in patients who developed clinically evident BIP showed that alterations in lung function assessments and chest radiography abnormalities are reversible in time,17 25 suggesting that the pulmonary changes due to bleomycin can be reversible, probably before the process of fibrosis starts definitely.

The mechanism of the endothelial damage, the primary event in the development of BIP, is not exactly known, but evidence is mounting that the induction of cytokines and free radicals is involved. These cytokines and free radicals can damage endothelial cells. Furthermore, the induced cytokines activate lymphocytes and upregulate adhesion molecules on endothelial cells, enabling the adhesion of activated inflammatory cells to the endothelium, the first step required for influx of these cells into the interstitium.27 The adhered lymphocytes also contribute to the endothelial damage by inducing apoptosis.28 29 After bleomycin exposure, increased expression of Fas messenger RNA in pulmonary endothelial cells and upregulation of its ligand, FasL, on lymphocytes resulting in apoptosis of the endothelial cells have been described.28 The progression of BIP could be prevented by pretreatment with soluble Fas antigen and anti-FasL-antibodies demonstrating the important role of this system.29

One of the primary sources of the cytokines involved in BIP is the macrophage. In vitro, bleomycin activates human alveolar macrophages that subsequently produce cytokines such as tumor necrosis factor (TNF)-{alpha} and interleukin (IL)-1ß.30 In animals, several studies31 32 33 34 have shown significant increases in protein or messenger RNA of TNF-{alpha} and IL-1ß in lungs after systemic or intratracheal administration of bleomycin. In humans, TNF-{alpha} is also induced by bleomycin. A significant rise in TNF-{alpha} plasma levels has been described 3 h, 4.5 h, and 24 h after administration of bleomycin in testicular cancer patients.35 Animal studies underlining the important role of these cytokines in the development of BIP showed that the development of BIP can be prevented by the administration of antibodies against TNF-{alpha}34 or by IL-1–receptor antagonists.36

The free radicals that contribute to the endothelial damage37 are produced by bleomycin directly after oxidation of the bleomycin-Fe (II) complex3 4 5 and by activated polymorphonuclear leukocytes.38 The importance of iron and free radicals in the pathogenesis of BIP is shown by prevention of BIP by dexrazoxane39 or amifostine,40 respectively.

After the damage of the endothelial cells and the subsequent infiltration of inflammatory cells into the interstitium, fibroblasts are activated with the accompanying deposit of collagen. These fibroblasts are activated by bleomycin directly41 and indirectly by bleomycin-induced cytokines such as TNF-{alpha}.42 43 In the process of collagen production by fibroblasts, transforming growth factor (TGF)-ß is one of the central mediators, as has been shown by a study in animals44 showing the prevention of BIP by antibodies against TGF-ß. After administration of bleomycin to animals, TGF-ß has been shown in several cell types in the lungs, such as in macrophages, fibroblasts, endothelial cells, and eosinophils.45 Also, this TGF-ß can be induced by bleomycin46 as well as the other cytokines induced by bleomycin.47


   Pulmonary Function Assessments
TOP
 Abstract
 Introduction
 Clinical Features
 Pathogenesis
 Pulmonary Function Assessments
Risk Factors
 Prevention and Treatment of...
 Conclusion
 References
 
Numerous methods such as cell counts in BAL fluid, gallium lung scanning, angiotensin-converting enzyme plasma levels, chest radiographs, or CT scans have been evaluated to detect BIP at an early stage, in order to avoid the further development of severe BIP by withholding further treatment with bleomycin.16 Pulmonary function assessments, however, seem to be the most proper tool.

Comis et al48 were the first to show a decrease in the transfer capacity of the lungs for carbon monoxide (TLCO) during bleomycin-containing multidrug chemotherapy. This observation was confirmed by several subsequent studies.49 50 51 Based on the histologic changes observed in the lungs after bleomycin exposure in animals, this decline in TLCO was considered to be due to bleomycin alone. Several studies48 49 50 52 53 54 have examined whether deterioration of TLCO was sensitive for detecting BIP and predictive for the development of clinical significant BIP. Although data from these studies are rather conflicting, several authors48 55 56 57 58 advised stopping further treatment with bleomycin when TLCO decreases > 40% or 60% of the pretreatment value.

Because bleomycin is almost always used in combination with other drugs that may also affect pulmonary function assessments, we previously performed a study to test the specificity of pulmonary function tests for bleomycin-induced pulmonary alterations.59 Pulmonary function assessments were carried out in 54 patients with disseminated testicular cancer randomized to treatment with 360 mg of bleomycin, etoposide, and cisplatin (BEP) or with etoposide and cisplatin (EP) only. During treatment, a decline of TLCO was found in both groups, and only at the end of therapy the TLCO was significantly decreased in the BEP compared with the EP group.59 It can be concluded that alterations in TLCO during bleomycin-containing multidrug chemotherapy are not a proper tool for monitoring BIP and, thus, cannot be used for decisions regarding further bleomycin treatment.

Two other pulmonary function tests, however, the vital capacity (VC) and the pulmonary capillary blood volume, showed decreased values only in the patients treated with BEP, while remaining stable in the EP patients.59 Therefore, these two parameters are more specific for bleomycin-induced changes. The VC has been shown to decrease more in patients developing BIP.50 Also, the total lung capacity (TLC), a parameter that, like the VC, reflects changes in lung volume, has been reported49 60 to decrease significantly in patients developing BIP compared with those who did not.

Therefore, combined with clinical symptoms, lung function assessments reflecting lung volumes such as VC and TLC can be used for patients suspected of developing BIP. It has to be kept in mind, however, that there is no association between pulmonary symptoms and decline of lung function assessments.57


   Risk Factors
TOP
 Abstract
 Introduction
 Clinical Features
 Pathogenesis
 Pulmonary Function Assessments
 Risk Factors
Prevention and Treatment of...
 Conclusion
 References
 
Many studies have been performed to identify risk factors for the development of BIP. However, most of these studies have used different criteria for its diagnosis. Furthermore, for establishing BIP, many studies used lung function assessments that have been shown later not to be specific for BIP when bleomycin is used in a multidrug regimen. In these circumstances and by these lung function assessments, pulmonary toxicity of bleomycin cannot be distinguished from pulmonary effects of other agents used. Therefore, comparison between studies is severely hampered, while others are not suitable for the purpose for which they were designed. Only studies that use BIP-specific lung function assessments, clinical symptoms or signs, or postmortem data are suitable for identification of risk factors of BIP.

Some studies61 62 suggest that the route by which bleomycin is administrated may affect bleomycin-induced toxicity. Bleomycin continuously infused may induce less toxicity than bolus injection.61 62 Decreased toxicity has also been described for IM administration compared to the IV route. However, other studies21 63 failed to show a relation between route of administration and toxicity. Therefore, bleomycin is mostly given IV in 30 to 60 min, enabling administration in an outpatient setting.

In animals, a linear positive relation between dose and severity of BIP has been found.64 65 Several studies11 66 67 suggested a similar relation in humans as well. For instance, in patients receiving a cumulative dose of < 300 mg of bleomycin, the incidence of BIP is 3 to 5%, while in patients treated with > 500 mg, 20% of the patients develop BIP.67 However, this dose-toxicity relationship in humans is less clear than it is in animals. Fatal BIP has been described in patients treated with < 100 mg of bleomycin, while in others receiving > 500 mg, no pulmonary toxicity occurred.68 69 70 Recently, Simpson et al19 described 180 patients treated with bleomycin and they did not find a significant difference in the cumulative dose of bleomycin between patients who died of BIP and those who did not. However, because of the increased incidence of BIP in patients treated with high doses, it is generally recommended to keep the total dose of bleomycin < 400 mg.

Age of the patients is also an established risk factor for the development of BIP. Elderly patients have an increased susceptibility to develop BIP, especially those > 70 years,17 21 but BIP has been reported also in much younger patients. One study19 described that the occurrence of fatal BIP increased with each decade after the age of 30 years. The exact reason for this increased risk is not known; it may be that decreased radical scavenging or a physiologic decline of renal function of elderly is involved.

Several studies71 72 aimed to reveal whether a smoking history increased the risk for BIP. An increased risk in smokers is strongly suggested by the study by Lower et al.72 These authors showed radiographic alterations consistent with BIP in 55% of the smoking patients receiving bleomycin compared with 0% of the nonsmokers.72

Bleomycin is mainly excreted by the kidneys, and deterioration of renal function has been shown to prolong bleomycin clearance. Crooke et al6 showed that terminal elimination half-life of bleomycin is not increased until a creatinine clearance of 25 to 35 mL/min, suggesting increased risk of BIP only in case of severe renal dysfunction. However, the study by Hall et al73 showed that bleomycin clearance is positively correlated with serum creatinine, suggesting enhanced bleomycin-induced effects in lesser degrees of renal dysfunction already. In accordance with this, many other studies19 74 75 showed a relationship between decline of renal function and increased bleomycin lung effects. Because bleomycin is often combined with nephrotoxic agents such as cisplatin, special attention should be paid for the development of BIP in patients with prior or developing renal dysfunction during therapy.

Radiotherapy exerts its function by the induction of free radicals, and radiotherapy of the chest is feared for the development of pulmonary fibrosis. Theoretically, the combination of radiotherapy and bleomycin could be a synergistic one. However, the most recent studies57 76 found only a slightly increased occurrence of pulmonary symptoms in patients treated with the combination compared to patients treated with bleomycin or radiotherapy alone. Pulmonary symptoms are most pronounced during therapy, while there is no evident increase of long-term sequelae. For instance, in patients with Hodgkin’s disease, >= 3 years after treatment with mediastinal radiotherapy (median dose, 44 Gy) and bleomycin (median dose, 120 U/m2), 37% of the patients had a FVC of < 80% predicted compared with 32% and 19% of the patients treated, respectively, with mediastinal radiotherapy or bleomycin alone.76 Hirsch et al57 showed that in patients with Hodgkin’s disease treated with bleomycin-containing multidrug therapy (median dose, 120 U/m2) followed by radiotherapy (median dose 36 Gy), a significantly higher percentage of patients developed pulmonary symptoms such as cough, shortness of breath, and oxygen requirement within 6 months after treatment compared with patients treated with chemotherapy only (50% vs 21%). However, 15 months after treatment there were no significant differences between both groups regarding pulmonary symptoms or functions.57 It can be concluded that the combination of bleomycin-containing chemotherapy and radiation is not paralleled with an excess of toxicity, but that especially during treatment, physicians must be beware of the development of pulmonary toxicity.

Because bleomycin is assumed to induce its toxicity partially by the induction of free radicals, the administration of high inspired oxygen could be hazardous. In most studies64 77 78 carried out in animals, such a relation has been shown. For instance, in hamsters treated with bleomycin and 70% oxygen for 72 h, the mortality was 90% compared with 15% in those animals that received bleomycin only.64 In humans, clear data showing an increased risk of BIP with concomitant oxygen supplementation are lacking; however, because of the data obtained from animal studies, oxygen supplementation is discouraged during bleomycin treatment. Because it is also not clear whether prior bleomycin therapy increases pulmonary toxicity induced by the administration of oxygen during surgery, Donat and Levy79 studied 77 patients with disseminated germ-cell tumors undergoing surgical resection for residual mass after bleomycin-containing chemotherapy (mean, 6.4 months). These authors did not show a significant difference in length and dose of administered fractional inspired oxygen between the 58 patients with no problems and the 19 patients with postoperative pulmonary problems, such as decreased oxygen saturation, pulmonary edema, or dyspnea, requiring treatment.79

Because of the important role of bleomycin-induced cytokines in the development of BIP, the increased application of growth factors in patients receiving chemotherapy could theoretically be paralleled by an increased incidence of BIP. These growth factors such as granulocyte-colony stimulating factor (G-CSF) can induce other cytokines involved in the pathogenesis of BIP. Although some case reports80 81 suggested increased risk of BIP in patients treated with growth factors such as G-CSF, one study found no increase of BIP in 29 patients coadministered G-CSF and bleomycin-containing chemotherapy compared with 57 patients receiving bleomycin-containing therapy only.60


   Prevention and Treatment of BIP
TOP
 Abstract
 Introduction
 Clinical Features
 Pathogenesis
 Pulmonary Function Assessments
 Risk Factors
 Prevention and Treatment of...
Conclusion
 References
 
Probably one of the most efficient ways to prevent BIP is to lower the total cumulative dose of bleomycin. Therefore, several studies18 82 83 have been performed in good-prognosis germ-cell cancer to establish the role of bleomycin; these studies showed that bleomycin could not be omitted completely from combination chemotherapy. However, Einhorn et al84 showed that lowering the total dose of bleomycin from 360 to 270 mg does not reduce efficacy of the treatment of good-prognosis disseminated testicular cancer.84 Therefore, 270 mg of bleomycin is considered to be the total dose in combination chemotherapy for disseminated good-prognosis germ-cell cancer in Europe as well as in the United States.85 86

In case of an unacceptable high risk for the development of BIP, physicians can consider treating patients with germ-cell cancer with etoposide, ifosfamide, and cisplatin instead of with the standard therapy, BEP. Etoposide, ifosfamide, and cisplatin have been shown to have an equal efficacy as BEP but at the costs of increased bone marrow suppression.87 88

The other malignancy for which bleomycin is often applied is Hodgkin’s disease. The total cumulative dose of bleomycin is 120 mg/m2 in many regimens. Although the main cause of pulmonary toxicity during treatment is the applied radiotherapy, in case of a high risk of BIP, nonbleomycin-containing regimens such as mechlorethamine, vincristine, procarbazine, and prednisone89 or procarbazine, melphalan, and vinblastine90 can be used.

In animals, several agents have been successfully tested for prevention or attenuation of BIP, such as soluble Fas antigen,28 IL-1–receptor antagonists,36 keratinocyte growth factor,91 cyclosporin92 or antibodies against TNF-{alpha},34 CD3 receptor,93 Fas ligand,29 or TGF-ß.44 Also, dexrazoxane39 and amifostine,40 which both affect bleomycin-induced free radicals and which are already clinically applied for decreasing chemotherapy-induced toxicity, have been shown to be effective in animals. Drugs that turned out not to be capable of affecting BIP are enoxaparin,94 pentoxifylline, and linomide.95 Studies establishing agents that may prevent BIP in humans have, however, not been performed yet (to my knowledge).

When clinical BIP occurs, the most widely applied agents are corticosteroids in high dosages (prednisone, 60 to 100 mg/d). In animals, the data on the efficacy of corticosteroids for BIP are rather conflicting.28 96 In humans, several case reports describe successful treatment of pulmonary symptoms during bleomycin treatment with corticosteroids. However, it might be possible that in several of these cases, the diagnosis was not BIP, but BOOP or eosinophilic hypersensitivity, both of which are known to react on treatment with corticosteroids. The study of White and Stover20 suggests some effects of corticosteroids in the treatment of BIP. These authors describe 10 patients with clinically evident BIP, 7 of whom were treated with corticosteroids. Initially, all treated patients showed clinical and radiographic improvement, while lowering the dose of corticosteroids resulted in recurrence of symptoms in five of the seven patients. All three untreated patients died early, while three of seven of the treated patients died 12 to 15 months after the beginning of BIP.20 However, besides this study, there are no other studies supporting the efficacy of corticosteroids in the treatment of BIP, while randomized studies are missing.

So, it can be concluded that when pulmonary symptoms start suddenly during bleomycin treatment and infections are excluded, the administration of corticosteroids is indicated because of a high risk of BOOP or eosinophilic hypersensitivity. For pulmonary symptoms starting more gradually and compatible with BIP, there are no convincing data for corticosteroids. In case of BIP, most important is that further bleomycin administration is withheld. When patients survive BIP, the pulmonary symptoms and disturbances in function assessment will almost always normalize in time.17 25


   Conclusion
TOP
 Abstract
 Introduction
 Clinical Features
 Pathogenesis
 Pulmonary Function Assessments
 Risk Factors
 Prevention and Treatment of...
 Conclusion
References
 
BIP is a severe and sometimes fatal side effect of bleomycin therapy. Numerous studies have been performed to identify methods capable of detecting BIP at an early preclinical stage. Combined with clinical signs and symptoms, pulmonary function tests reflecting lung volume such as TLC and VC are probably most suitable for this purpose. Identification of risk factors has probably resulted in decreased bleomycin-induced morbidity and mortality, but this has never been examined (to my knowledge). Increased knowledge of the pathogenesis may lead to agents capable of attenuating or preventing BIP, such as dexrazoxane, which may even permit higher bleomycin doses. Until that time, physicians administrating bleomycin have to be aware of the development of BIP, especially in the presence of risk factors (Table 1 ).


View this table:
[in this window]
[in a new window]

  		Table 1.. Characteristics of BIP

 


   Footnotes
 
Abbreviations: BEP = bleomycin, etoposide, cisplatin; BIP = bleomycin-induced pneumonitis; BOOP = bronchiolitis obliterans with organizing pneumonia; EP = etoposide, cisplatin; G-CSF = granulocyte-colony stimulating factor; IL-interleukin; TGF = transforming growth factor; TLC = total lung capacity; TLCO = transfer capacity of the lungs for carbon monoxide; TNF = tumor necrosis factor; VC = vital capacity

Received for publication July 31, 2000. Accepted for publication January 23, 2001.


   References
TOP
 Abstract
 Introduction
 Clinical Features
 Pathogenesis
 Pulmonary Function Assessments
 Risk Factors
 Prevention and Treatment of...
 Conclusion
 References
 

  1. Umezawa, H, Meaeda, K, Takeuchi, T, et al (1966) New antibiotics, bleomycin A and B. J Antibiot Ser A 19,200-205
  2. Schirner, M, Hoffmann, J, Menrad, A, et al (1998) Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res 4,1331-1336[Abstract]
  3. Sausville, EA, Peisach, J, Horwitz, SB (1978) Effect of chelating agents and metal ions on the degradation of DNA by bleomycin. Biochem 17,2740-2746[CrossRef][Medline]
  4. Sausville, EA, Stein, RW, Peisach, J, et al (1978) Properties and products of the degradation of DNA by bleomycin and iron. Biochemistry 17,2746-2754[CrossRef][Medline]
  5. Burger, RM, Pesach, J, Horwitc, SB (1981) Activated bleomycin: a transient complex of drug, iron and oxygen that degradates DNA. J Biol Chem 256,11636-11644[Abstract/Free Full Text]
  6. Crooke, ST, Comis, RL, Einhorn, LH, et al (1977) Effects of variations in renal function on the clinical pharmacology of bleomycin administrated as an iv bolus. Cancer Treat Rep 61,1631-1636[ISI][Medline]
  7. Umezawa, H, Takeiuechi, T, Hosi, S, et al (1972) Studies on the mechanism of antitumor effect of bleomycin in squamous cell carcinoma. J Antibiot 25,409-420[Medline]
  8. Ohnuma, T, Holland, JF, Masuda, H, et al (1974) Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance. Cancer 33,1230-1238[CrossRef][Medline]
  9. Rosenfelt, F, Palmer, J, Weinstein, I, et al (1982) A fatal hyperpyrexial response to bleomycin following prior therapy: a case report and literature review. Yale J Biol Med 55,529-531[ISI][Medline]
  10. Leung, WH, Lau, JYN, Chan, TK, et al (1989) Fulminant hyperpurexia induced by bleomycin. Postgrad Med J 65,417-419[Abstract]
  11. Blum, R, Carter, SK, Agre, K (1973) A clinical review of bleomycin: a new antineoplastic agent. Cancer 31,903-914[CrossRef][ISI][Medline]
  12. Santrach, PJ, Askin, FB, Wells, RJ, et al (1989) Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer 64,806-811[CrossRef][ISI][Medline]
  13. Holoye, PY, Luna, MH, Mackay, B, et al (1978) Bleomycin hypersensitivity pneumonitis. Ann Intern Med 88,47-49
  14. Van Barneveld, PWC, Van der Mark, TW, Sleijfer, DT, et al (1984) Predictive factors for bleomycin-induced pneumonitis. Am Rev Respir Dis 130,1078-1081[ISI][Medline]
  15. Dearnaley, DP, Horwich, A, A’Hern, R, et al (1981) Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. Eur J Cancer 27,684-691
  16. Jules-Elysee, K, White, DA (1990) Bleomycin-induced pulmonary toxicity. Clin Chest Med 11,1-20[ISI][Medline]
  17. De Lena, M, Guzzon, A, Monfardini, S, et al (1972) Clinical, radiologic and histopathological studies on pulmonary toxicity induced by treatment with bleomycin (N.S.C.-125066) Cancer Chemother Rep 56,343-355
  18. Levi, JA, Raghaven, D, Harvey, V, et al (1993) The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. J Clin Oncol 11,1300-1305[Abstract/Free Full Text]
  19. Simpson, AB, Paul, J, Graham, J, et al (1998) Fatal bleomycin pulmonary toxicity in the west of Scotland 1991–95; a review of patients with germ cell tumours. Br J Cancer 78,1061-1066[ISI][Medline]
  20. White, DA, Stover, DE (1984) Severe bleomycin-induced pneumonitis: clinical features and response to corticosteroids. Chest 86,723-728[Abstract/Free Full Text]
  21. Yagoda A, Makherjib, Young C, et al. Bleomycin: an antitumor antibiotic; clinical experience in 274 patients. Ann Intern Med 1972; 77:861–870
  22. Rimmer, MJ, Dixon, AK, Flower, CDR, et al (1985) Bleomycin-lung: CT observations. Br J Radiol 58,1041-1045[Abstract]
  23. Jones, AW (1978) Bleomycin lung damage: the pathology and nature of the lesion. Br J Dis Chest 72,321-326[ISI][Medline]
  24. Bedrossian, LWM, Luna, MA, Mackay, B, et al (1973) Ultrastructure of pulmonary bleomycin toxicity. Cancer 32,44-51[CrossRef][ISI][Medline]
  25. Van Barneveld, PWC, Sleijfer, DT, Van der Mark, TW, et al (1987) The natural course of bleomycin induced pneumonitis (BIP): a follow-up study in eight patients. Am Rev Respir Dis 135,48-51[ISI][Medline]
  26. Adamson, IYR, Bowden, DH (1974) The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 77,185-191[ISI][Medline]
  27. Piguet, PF, Rosen, H, Vesin, C, et al (1993) Effective treatment of the pulmonary fibrosis elicited in mice by bleomycin or silica with anti-CD-11 antibodies. Am Rev Respir Dis 147,435-441[ISI][Medline]
  28. Hagimoto, N, Kuwano, K, Nomoto, Y, et al (1997) Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 16,91-101[Abstract]
  29. Kuwano, K, Hagimoto, N, Kawasaki, M, et al (1999) Essential roles of the Fas/Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 104,13-19[ISI][Medline]
  30. Scheule, RK, Perkins, RC, Hamilton, R, et al (1992) Bleomycin stimulation of cytokine secretion by the human alveolar macrophage. Am J Physiol 262,L386-L391[Abstract/Free Full Text]
  31. Phan, SH, Kunkel, SL (1992) Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res 18,29-43[ISI][Medline]
  32. Santana, A, Saxena, B, Noble, NA, et al (1995) Increased expression of transforming growth factor ß isoforms (ß 1, ß 2, ß 3) in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 13,34-44[Abstract]
  33. Gurujeyalakshmi, G, Giri, SN (1995) Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-ß and procollagen I and III gene expression. Exp Lung Res 21,791-808[ISI][Medline]
  34. Piguet, PF, Collart, MA, Grau, GE, et al (1989) Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 170,655-663[Abstract/Free Full Text]
  35. Sleijfer, S, Vujaskovic, Z, Limburg, PC, et al (1998) Induction of tumor necrosis factor-{alpha} as a cause of bleomycin-related toxicity. Cancer 4,970-974
  36. Piguet, PF, Vesin, C, Grau, GE, et al (1993) Interleukin 1 receptor antagonist (IL1-ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 5,57-61[CrossRef][ISI][Medline]
  37. Doelman, CJA, Bast, A (1990) Oxygen radicals in lung pathology. Free Radic Biol Med 9,381-400[CrossRef][ISI][Medline]
  38. Moseley, PL, Shasby, DM, Brady, M, et al (1984) Lung parenchymal injury induced by bleomycin. Am Rev Respir Dis 130,1082-1086[ISI][Medline]
  39. Herman, EH, Hasinoff, BB, Zhang, J, et al (1995) Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity. Toxicology 98,163-175[CrossRef][ISI][Medline]
  40. Nici, L, Calabresi, P (1999) Amifostine modulation of bleomycin-induced lung injury in rodents. Semin Oncol 26,28-33
  41. Moseley, PL, Hemken, C, Hunninghake, GW (1986) Augmentation of fibroblast proliferation by bleomycin. J Clin Invest 78,1150-1154
  42. Sugerman, BJ, Aggarwal, BB, Figari, IS, et al (1985) Recombinant human tumor necrosis factor {alpha}: effects on proliferation of normal and transformed cells in vitro. Science 230,943-945[Abstract/Free Full Text]
  43. Schmidt, JA, Mizel, SB, Cohen, D, et al (1982) Interleukin-1: a potential regulator of fibroblast proliferation. J Immunol 128,2177-2182[ISI][Medline]
  44. Giri, SN, Hyde, DM, Hollinger, MA (1993) Effect of antibody to transforming growth factor ß on bleomycin induced accumulation of lung collagen in mice. Thorax 48,959-966[Abstract/Free Full Text]
  45. Zhang, K, Flanders, KC, Phan, SH (1995) Cellular localization of transforming growth factor-ß expression in bleomycin-induced pulmonary fibrosis. Am J Pathol 147,352-361[Abstract]
  46. Phan, SH, Gharaee-Kermani, M, Wolber, F, et al (1991) Stimulation of rat endothelial cell transforming growth factor-ß production by bleomycin. J Clin Invest 87,148-154
  47. Phan, SH, Gharaee-Kermani, M, McGarry, B, et al (1992) Regulation of rat pulmonary artery endothelial cell transforming growth factor-ß production by IL-1-ß and tumor necrosis factor-{alpha}. J Immunol 149,103-106[Abstract]
  48. Comis, RL, Kuppinger, MS, Ginsberg, SJ, et al (1979) Role of single-breath carbon monoxide diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients. Cancer Res 39,5076-5080[Abstract/Free Full Text]
  49. Wolkowicz, J, Sturgeon, J, Ravji, M, et al (1992) Bleomycin-induced pulmonary function abnormalities. Chest 101,97-101[Abstract/Free Full Text]
  50. Van Barneveld, PWC, Veenstra, G, Sleijfer, DT, et al (1985) Changes in pulmonary functions during and after bleomycin treatment in patients with testicular carcinoma. Cancer Chemother Pharmacol 14,168-171[CrossRef][ISI][Medline]
  51. Luursema, PB, Star-Kroesen, MA, Van der Mark, TW, et al (1983) Bleomycin-induced changes in the carbon monoxide transfer factor of the lung and its components. Am Rev Respir Dis 128,880-883[ISI][Medline]
  52. Sorensen, PG, Rossing, N, Roth, M (1985) Carbon monoxide diffusing capacity: a reliable indicator of bleomycin-induced pulmonary toxicity. Eur J Respir Dis 66,333-340[ISI][Medline]
  53. Lucraft, HH, Wilkinson, PM, Stretton, TB, et al (1982) Role of pulmonary function tests in the prevention of bleomycin pulmonary toxicity during chemotherapy for metastatic testicular teratoma. Eur J Cancer Clin Oncol 18,133-139[CrossRef][ISI][Medline]
  54. McKeage, MJ, Evans, BD, Atkinson, C, et al (1990) Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. J Clin Oncol 8,779-783[Abstract]
  55. Comis, RL (1990) Detecting bleomycin pulmonary toxicity: a continued conundrum. J Clin Oncol 8,765-767[ISI][Medline]
  56. Comis, RL (1992) Bleomycin pulmonary toxicity: current status and future directions. Semin Oncol 19(suppl 5),64-70
  57. Hirsch, A, Vander Els, N, Straus, DJ, et al (1996) Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin’s disease. J Clin Oncol 14,1297-1305[Abstract/Free Full Text]
  58. Jensen, JL, Goel, R, Venner, PM (1990) The effect of corticosteroid administration on bleomycin lung toxicity. Cancer 65,1291-1297[CrossRef][ISI][Medline]
  59. Sleijfer, S, Van der Mark, TW, Schraffordt Koops, H, et al (1995) Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect. Br J Cancer 71,120-123[ISI][Medline]
  60. Saxman, SB, Nichols, CR, Einhorn, LH (1997) Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating growth factor. Chest 111,657-660[Abstract/Free Full Text]
  61. Cooper, KR, Hong, WK (1981) Prospective study of the pulmonary toxicity of continuously infused bleomycin. Cancer Treat Rep 65,419-425[ISI][Medline]
  62. Carlson, RW, Sikic, BJ (1983) Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med 99,823-833
  63. Samuals, MI, Johnson, PE, Holoye, PY, et al (1976) Large-dose bleomycin therapy and pulmonary toxicity. JAMA 235,1117-1120[Abstract]
  64. Tryka, AF, Skornik, WA, Godleski, JJ, et al (1982) Potentiation of bleomycin-induced lung injury by exposure to 70% oxygen. Am Rev Respir Dis 126,1074-1076[ISI][Medline]
  65. Catravas, LD, Laza, JS, Dobuler, KJ, et al (1983) Pulmonary endothelial dysfunction in the presence or absence of interstitial injury induced by intratracheally injected bleomycin in rabbits. Am Rev Respir Dis 128,740-746[ISI][Medline]
  66. Haas, CD, Coltman, CA, Gottlieb, JA, et al (1976) Phase II evaluation of bleomycin: a southwest oncology group study. Cancer 38,8-12[CrossRef][ISI][Medline]
  67. Collis, CH (1980) Lung damage of cytotoxic drugs. Cancer Chemother Pharmacol 4,17-27[CrossRef][ISI][Medline]
  68. Bauer, KA, Skarin, AT, Balikian, JP, et al (1983) Pulmonary complications associated with combination chemotherapy programs containing bleomycin. Am J Med 74,557-563[CrossRef][ISI][Medline]
  69. Wilson, KS, Worth, SA, Richards, AG, et al (1982) Low-dose bleomycin lung. Med Pediatr Oncol 10,283-288[ISI][Medline]
  70. McLeod, BF, Lawrance, HJ, Smith, DW, et al (1987) Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency. Cancer 60,2617-2622[CrossRef][ISI][Medline]
  71. Parvinen, LM, Kilkku, P, Markinen, E, et al (1983) Factors affecting the pulmonary toxicity of bleomycin. Acta Radiol 22,417-422
  72. Lower, EE, Strohofer, S, Baughman, RP (1988) Bleomycin causes alveolar macrophages from cigarette smokers to release hydrogen peroxide. Am J Med Sci 295,193-197[ISI][Medline]
  73. Hall, SW, Strong, JE, Broughton, A, et al (1982) Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol 9,22-25[CrossRef][ISI][Medline]
  74. Sleijfer, S, Van der Mark, TW, Schraffordt Koops, H, et al (1996) Enhanced effects of bleomycin on pulmonary function assessments in patients with decreased renal function due to cisplatin. Eur J Cancer 32A,550-552
  75. Dalgleish, AG, Woods, RL, Levi, JA (1984) Bleomycin pulmonary toxicity: its relationship to renal dysfunction. Med Pediatr Oncol 12,313-317[ISI][Medline]
  76. Horning, SJ, Adhikari, A, Rizk, N, et al (1994) Effect of treatment for Hodgkin’s disease on pulmonary function: results of a prospective study. J Clin Oncol 12,297-305[Abstract]
  77. Sogal, RN, Gottlieb, AA, Boutros, AR, et al (1987) Effect of oxygen on bleomycin-induced lung damage. Cleve Clin J Med 54,503-509[ISI][Medline]
  78. Blom-Muilwijk, MC, Vriesendorp, R, Veninga, TS, et al (1988) Pulmonary toxicity after treatment with bleomycin alone or in combination with hyperoxia. Br J Anaesth 60,91-97[Abstract/Free Full Text]
  79. Donat, SM, Levy, DA (1998) Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary? J Urol 160,1347-1352[CrossRef][ISI][Medline]
  80. Dirix, L, Schrijvers, D, Drawe, P, et al (1997) Pulmonary toxicity and bleomycin [letter]. Lancet 344,56
  81. Matthews, J (1993) Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin’s disease: possible synergy. Lancet 342,988
  82. Loehrer, PJ, Johnson, D, Elson, P, et al (1995) Importance of bleomycin in favorable-prognosis disseminated germ-cell tumors: an Eastern Co-operative Oncology Group trial. J Clin Oncol 13,470-476[Abstract/Free Full Text]
  83. De Wit, R, Stoter, G, Kaye, SB, et al (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular non-seminoma: a randomised study of the EORTC genitourinary tract cancer co-operative group. J Clin Oncol 15,1837-1843[Abstract/Free Full Text]
  84. Einhorn, LH, Williams, SD, Loehrer, PJ, et al (1989) Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ-cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 7,387-391[Abstract]
  85. De Wit, R (1999) Treatment of disseminated non-seminomatous testicular cancer: the European experience. Semin Surg Oncol 17,250-256[CrossRef][ISI][Medline]
  86. Bosl, GJ (1999) Germ cell tumor clinical trials in North America. Semin Surg Oncol 17,257-262[CrossRef][ISI][Medline]
  87. Nichols, CR, Catalano, PJ, Crawford, ED, et al (1998) Randomised comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ-cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group study. J Clin Oncol 16,1287-1293[Abstract/Free Full Text]
  88. De Wit, R, Stoter, G, Sleijfer, DT, et al (1998) Four cycles of BEP vs. four cycles of VIP in patients with intermediate-prognosis metastatic non-seminoma: a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 78,828-832[ISI][Medline]
  89. Canellos, G, Anderson, J, Propert, K (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327,1478-1484[Abstract]
  90. Horning, SJ, Ang, PT, Hoppe, RT, et al (1992) The Stanford experience with combined procarbazine, alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin’s disease. Ann Oncol 3,747-754[Abstract/Free Full Text]
  91. Sugahara, K, Iyama, K, Kuroda, MJ, et al (1998) Double intratracheal installation of keratinocyte growth factor prevents bleomycin-induced lung fibrosis in rats. J Pathol 186,90-98[CrossRef][ISI][Medline]
  92. Lossos, IS, Or, R, Goldstein, RH, et al (1996) Amelioration of bleomycin-induced pulmonary injury by cyclosporin A. Exp Lung Res 22,337-349[ISI][Medline]
  93. Sharma, SK, MacLean, JA, Pinto, C, et al (1996) The effect of an anti-CD3 monoclonal antibody on bleomycin induced lymphokine production and lung injury. Am J Respir Dis 154,193-200
  94. Laxer, U, Lossos, IS, Gillis, S, et al (1999) The effect of enoxaparin on bleomycin-induced lung injury in mice. Exp Lung Res 25,531-541[CrossRef][ISI][Medline]
  95. Kremer, S, Breuer, R, Lossos, IS, et al (1999) Effect of immunomodulators on bleomycin-induced lung injury. Respiration 66,455-462[CrossRef][ISI][Medline]
  96. Nettelbladt, O, Tengblad, A, Hallgren, R (1990) High-dose corticosteroids during bleomycin-induced alveolitis in the rat do not suppress the accumulation of hyaluronan (hyaluronic acid) in lung tissue. Eur Respir J 3,421-428[Abstract]



This article has been cited by other articles:


Home page
 ChestHome page
M. C. B. Godoy, D. Nonaka, B. G. Raphael, and I. Vlahos
Diffuse Ground-Glass Opacities in a Patient With Hodgkin Lymphoma and Progressive Respiratory Failure
Chest, July 1, 2008; 134(1): 207 - 212.
[Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Kawai, S. Ando, S. Hinotsu, T. Oikawa, N. Sekido, N. Miyanaga, T. Shimazui, and H. Akaza
Completion and Toxicity of Induction Chemotherapy for Metastatic Testicular Cancer: An Updated Evaluation of Japanese Patients
Jpn. J. Clin. Oncol., July 1, 2006; 36(7): 425 - 431.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
T. Kimura, Y. Ishii, K. Yoh, Y. Morishima, T. Iizuka, T. Kiwamoto, Y. Matsuno, S. Homma, A. Nomura, T. Sakamoto, et al.
Overexpression of the Transcription Factor GATA-3 Enhances the Development of Pulmonary Fibrosis
Am. J. Pathol., July 1, 2006; 169(1): 96 - 104.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
L. Joos and M. Tamm
Breakdown of Pulmonary Host Defense in the Immunocompromised Host: Cancer Chemotherapy
Proceedings of the ATS, December 1, 2005; 2(5): 445 - 448.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. G. Martin, K. M. Ristow, T. M. Habermann, J. P. Colgan, T. E. Witzig, and S. M. Ansell
Bleomycin Pulmonary Toxicity Has a Negative Impact on the Outcome of Patients With Hodgkin's Lymphoma
J. Clin. Oncol., October 20, 2005; 23(30): 7614 - 7620.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. Nakatani-Okuda, H. Ueda, S.-i. Kashiwamura, A. Sekiyama, A. Kubota, Y. Fujita, S. Adachi, Y. Tsuji, T. Tanizawa, and H. Okamura
Protection against bleomycin-induced lung injury by IL-18 in mice
Am J Physiol Lung Cell Mol Physiol, August 1, 2005; 289(2): L280 - L287.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. M. Arnaboldi, M. J. Behr, and D. W. Metzger
Mucosal B Cell Deficiency in IgA-/- Mice Abrogates the Development of Allergic Lung Inflammation
J. Immunol., July 15, 2005; 175(2): 1276 - 1285.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
V. Garipidou, S. Vakalopoulou, E. Zafiriadou, V. Kaloutsi, K. Tziomalos, and V. Perifanis
Uncommon manifestation of bleomycin-induced pulmonary toxicity in a patient with Hodgkin's disease
Ann. Onc., March 1, 2005; 16(3): 514 - 515.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
T. Genovese, S. Cuzzocrea, R. Di Paola, E. Mazzon, C. Mastruzzo, P. Catalano, M. Sortino, N. Crimi, A. P. Caputi, C. Thiemermann, et al.
Effect of rosiglitazone and 15-deoxy-{Delta}12,14-prostaglandin J2 on bleomycin-induced lung inju